natgillin/translations-raw huggingface dataset:
Less potent inducers (e.g., efavirenz, nevirapine, etravirine, rifabutin, glucocorticoids, St. John's wort, pioglitazone) may be used with the recommended dose of ISENTRESS.
Manj močne induktorje (npr. efavirenz, nevirapin, etravirin, rifabutin, glukokortikoide, šentjanževko, pioglitazon) se lahko uporablja skupaj s priporočenim odmerkom zdravila ISENTRESS.
Less pronounced reductions of metabolite exposure has been observed with pantoprazole or lansoprazole.
Manj izrazito zmanjšanje izpostavljenosti presnovku je bila opažena pri pantoprazolu ali lansoprazolu.
Less than 0.9% of a topically applied single dose of radiolabelled imiquimod was absorbed through the skin of human subjects.
Pri ljudeh se je manj kot 0,9% topično nanesenega odmerka radioaktivno označenega imikvimoda absorbiralo skozi kožo.
Less than 1% of ceftazidime is excreted via the bile and less than 0.25% of avibactam is excreted into faeces.
Manj kot 1 % ceftazidima se izloči z žolčem in manj kot 0,25 % avibaktama se izloči v blatu.
Less than 1% of intact active substance is excreted unchanged in the urine.
Manj kot 1 % snovi se nespremenjene izloča v urinu.
Less than 1% of intact active substance is excreted unchanged in the urine.
Manj kot 1 % zdravilne učinkovine se nespremenjene izloča v urinu.
Less than 1% of patients required permanent discontinuation of treatment in clinical studies with ceritinib (see section 4.4).
V kliničnih študijah s ceritinibom je bilo treba zdravljenje dokončno ukiniti pri manj kot 1 % bolnikov (glejte poglavje 4.4).
Less than 1% of Plegridy treated patients experienced a serious hypersensitivity event (e.g. angioedema, urticaria) and they recovered promptly after treatment with anti-histamines and/or corticosteroids.
Pri manj kot 1 % bolnikov, zdravljenih z zdravilom Plegridy, se je pojavil resen preobčutljivostni dogodek (npr. angioedem, urtikarija), po zdravljenju z antihistaminiki in/ali kortikosteroidi pa so hitro okrevali.
Less than 1% of the administered radioactive dose was excreted in the urine, indicating negligible renal clearance.
Manj kot 1 % apliciranega radioaktivnega odmerka se je izločil v urinu, kar kaže na zanemarljiv ledvični očistek.
Less than 1% of the parent drug is found in urine.
V urinu se pojavi manj kot 1 % izhodne učinkovine.
Less than 10%
manj kot 10
less than 12 hours have passed: take your capsule immediately. more than 12 hours have passed: do not take your capsule.
je minilo manj kot 12 ur: kapsulo vzemite takoj; je minilo več kot 12 ur: ne vzemite kapsule.
less than 12 hours have passed: take your capsules immediately. more than 12 hours have passed: do not take your capsules.
je minilo manj kot 12 ur: nemudoma vzemite kapsule. je minilo več kot 12 ur: ne vzemite kapsul.
Less than 14 kg
manj kot 14 kg
Less than 2% of an ocular dose of travoprost was recovered in urine as free acid.
Manj kot 2% okularnega odmerka travoprosta so našli v seču v obliki proste kisline.
Less than 2% of patients receiving Cerdelga permanently discontinued treatment due to any adverse reaction.
Manj kot 2 % bolnikov, ki so prejemali zdravilo Cerdelga, je trajno prekinila zdravljenje zaradi kateregakoli neželenega učinka.
Less than 25,000
manj kot 25.000
less than 28 weeks gestational age and/or body weight <1000g particularly when receiving parenteral nutrition with co-administration of medicinal products known to interfere with caffeine metabolism
z manj kot 28 tedni gestacijske starosti in/ali telesno maso < 1000 g, še posebej pri prejemanju parenteralne prehrane, s sočasnim dajanjem zdravil, ki motijo metabolizem kofeina.
Less than 3% of Sivextro administered dose is excreted as active tedizolid.
Manj kot 3 % uporabljenega odmerka zdravila Sivextro se izloči v obliki aktivnega tedizolida.
Less than 30 mL/min
manj kot 30 ml/min
Less than 5% of the dose is excreted unchanged in the urine and faeces.
Manj kot 5 % odmerka se izloči v nespremenjeni obliki z urinom ali blatom.
Less than 500
manj kot 500
Less than 6 hours until your next dose - do not take the missed dose, take your next dose as usual with food.
manj kot 6 ur do naslednjega odmerka - ne vzemite pozabljenega odmerka, ampak vzemite naslednji odmerek kot običajno s hrano.
less than 6 kg
manj kot 6 kg
Less than 9 % of patients discontinued due to any adverse event in the first year with the incidence of additional patient discontinuations being 3 % at both 2 and 3 years.
Manj kot 9 % bolnikov je prekinilo zdravljenje zaradi kateregakoli neželenega učinka v prvem letu, s 3 % porastom števila prekinitev zdravljenja bolnikov v 2. in 3. letu.
Less than 9% of patients discontinued due to any adverse event in the first year with the incidence of additional patient discontinuations being 3% at both 2 and 3 years.
Manj kot 9 % bolnikov je prekinilo zdravljenje zaradi kateregakoli neželenega učinka v prvem letu s 3 % porastom števila prekinitev zdravljenja bolnikov v 2. in 3. letu.
Less than 9% of patients discontinued due to any adverse event in the first year with the incidence of additional patient discontinuations being 3% at both 2 and 3 years.
Manj kot 9 % bolnikov je prekinilo zdravljenje zaradi kateregakoli neželenega učinka v prvem letu, s 3 % porastom števila prekinitev zdravljenja bolnikov v 2. in 3. letu.
Less than daily dosing
Manj kot dnevno odmerjanje:
Less toxicity and reduction in Grade 3/4 haematologic and non-haematologic toxicities such as neutropenia, febrile neutropenia and infection with Grade 3/4 neutropenia were reported when pre- treatment with folic acid and vitamin B12 was administered.
Poročali so o manjši toksičnosti in znižanju hematoloških in nehematoloških toksičnosti stopnje 3/4, kot je nevtropenija, febrilna nevtropenija ter okužba z nevtropenijo stopnje 3/4, kadar so pred zdravljenjem dajali folno kislino in vitamin B12.
Less toxicity and reduction in Grade 3/4 haematologic and non-haematologic toxicities such as neutropenia, febrile neutropenia and infection with Grade 3/4 neutropenia were reported when pre- treatment with folic acid and vitamin B12 was administered.
Poročali so o povprečno manjši toksičnosti ter znižanju hematoloških in nehematoloških toksičnosti stopnje 3/4, denimo nevtropeniji, febrilni nevtropeniji ter okužbi z nevtropenijo stopnje 3/4, kadar so pred zdravljenjem dajali folno kislino in vitamin B12.
Less toxicity and reduction in Grade 3/4 haematologic and non-haematologic toxicities, such as neutropenia, febrile neutropenia, and infection with Grade 3/4 neutropenia, were reported when pre- treatment with folic acid and vitamin B12 was administered.
Poročali so o povprečno manjši toksičnosti ter znižanju hematoloških in nehematoloških toksičnosti stopnje 3/4, denimo nevtropeniji, febrilni nevtropeniji ter okužbi z nevtropenijo stopnje 3/4, kadar so pred zdravljenjem dajali folno kislino in vitamin B12.
Less toxicity and reduction in Grade 3/4 haematologic and non-haematologic toxicities, such as neutropenia, febrile neutropenia, and infection with Grade 3/4 neutropenia, were reported when pre-treatment with folic acid and vitamin B12 was administered.
Poročali so o povprečno manjši toksičnosti ter znižanju hematoloških in nehematoloških toksičnosti stopnje 3/4, denimo nevtropeniji, febrilni nevtropeniji ter okužbi z nevtropenijo stopnje 3/4, kadar so pred zdravljenjem dajali folno kislino in vitamin B12.
Let all the equipment dry in the air.
Vse pripomočke pustite na zraku, da se posušijo.
Let go of the lower lid, and close your eye..
Spustite spodnjo veko in zaprite oko.
Let go of the plunger allowing the syringe to move up inside the device until the entire needle is guarded.
Prenehajte s pritiskanjem na bat in namestite brizgo v prvotni položaj, tako da bo celotna igla zaščitena z zaščitnim pokrovčkom.
Let go of the plunger.
Bat sprostite.
Let go of the plunger.
Spustite bat.
Let go of the skin in your hand.
Spustite kožo v roki.
Let go of the tip of your penis and let your penis return to its normal length.
Izpustite konico penisa in počakajte, da se penis vrne na normalno dolžino.
Let it sit for about one minute until the medicine is completely mixed.
Pustite ga ležati približno eno minuto, dokler se zdravilo popolnoma ne zmeša.
Let the injection site dry before injecting the dose.
Pred injiciranjem odmerka počakajte, da se mesto injiciranja osuši.
Let the insulin reach room temperature before you use it.
Pred uporabo počakajte, da se insulin segreje na sobno temperaturo.
Let the insulin reach room temperature before you use it.
Preden insulin uporabite, ga pustite, da doseže sobno temperaturo.
Let the insulin reach room temperature before you use it.
Preden uporabite injekcijski vložek, ga pustite da doseže sobno temperaturo.
Let the kit stand unopened for 15 minutes.
Zaprt komplet pustite, da stoji približno 15 minut.
Let the liquid get back to room temperature before using.
Pred uporabo pustite, da se raztopina ogreje na sobno temperaturo.
Let the liquid stand for 10 minutes and most of the bubbles will disappear.
Tekočino pustite, naj 10 minut stoji, tako bo večina mehurčkov izginila.
Let the liquid stand for 10 minutes in order for most of the bubbles to disappear.
Pustite, naj tekočina stoji 10 minut, da bo večina mehurčkov izginila.
Let the skin dry for approximately 10 seconds.
Počakajte približno 10 sekund, da se koža osuši.
Let the syringe dry completely before you use that syringe for dosing.
Brizgo popolnoma posušite preden jo ponovno uporabite za odmerjanje.
Let the syringe warm up
Počakajte, da se injekcijska brizga segreje na sobno temperaturo
Let the tops dry in the air.
Pustite, da se površina posuši na zraku.
Let the vial rest for about two minutes.
Pustite vialo mirovati približno dve minuti.
Let the water flow slowly down the inside of the vial.
Voda naj znotraj viale počasi teče navzdol.
Let your doctor know if you think you need more medicine than prescribed.
Ne jemljite več zdravila kot je predpisano.
Let your injection site dry on its own before injecting your dose.
Pred injiciranjem odmerka počakajte, da se mesto injiciranja samo osuši.
Let your pen warm up.
Pustite, da se peresnik ogreje.
Lethargy (G3/4: 3.4%);
letargija (S 3/4: 3,4 %), pireksija (S 3/4:
lethargy / weakness
letargija/šibkost
lethargy or fatigue (unusual tiredness or exhaustion) flu-like syndrome (joint and muscle pain with fever)
letargijo ali utrujenost (neobičajno utrujenost ali izčrpanost) gripi podoben sindrom (bolečine sklepov in mišic z zvišano
Lethargy Somnolence
letargija, somnolenca
Lethargy Tremor
letargija tremor
Lethargy, ataxia, emesis, anorexia, diarrhoea, excessive salivation, hyperglycaemia, increased sensitivity to stimulation, bradycardia or bradypnea may be observed.
Lahko se pojavijo letargija, ataksija, bruhanje, anoreksija, driska, prekomerno slinjenje, hiperglikemija, povečana občutljivost na dražljaje, bradikardija ali bradipneja.
Lethargy, hypoaesthesia, syncope, dysaesthesia
letargija, hipoestezija, sinkopa, disestezija
lethargy, malaise)
(vključno z vulvovaginalnim
lethargy, migraine
otopelost, migrena
Lethargy, paraesthesia, somnolence, tremor, syncope, dysgeusia
letargija, parestezija, somnolenca, tremor, sinkopa, motnje okušanja
Lethargy, sickness, restlessness
zaspanost (letargija), slabost, nemirnost,
Lethargy; Pain
Letargija
Lethargy; Pain
letargija, bolečina
Lethargy; Pain
Letargija, bolečine
LETIFEND solvent for dogs
LETIFEND vehikel za pse
Letrozole 2.5 mg /day
letrozol 2,5 mg/dan
Leucocytes decreased
Znižani levkociti
Leucocytes decreasedh
zmanjšano število levkocitovh
Leucocytoclastic vasculitis, angioedema, erythema multiforme, flushing
levkocitoklastični vaskulitis, angioedem, multiformni eritem, oblivanje
Leucocytosis
levkocitoza
leucocytosis,
levkocitoza,
Leucofeligen FeLV/RCP contains small amounts of the three types of weakened virus listed above and protein from the FeLV called ‘envelope p45 protein’.
Cepivo Leucofeligen FeLV/RCP vsebuje majhne količine treh vrst oslabljenih virusov, ki so našteti zgoraj, in beljakovino iz FeLV, imenovano beljakovina ovojnice p45.
Leucofeligen FeLV/RCP has been examined in two main ‘field’ studies involving kittens aged eight to nine weeks.
Cepivo Leucofeligen FeLV/RCP je bilo proučeno v dveh glavnih študijah na terenu z mačjimi mladiči, starimi od osem do devet tednov.
Leucofeligen FeLV/RCP is a vaccine for cats.
Leucofeligen FeLV/RCP je cepivo za mačke.
Leucofeligen FeLV/RCP is a vaccine.
Leucofeligen FeLV/RCP je cepivo.
Leucofeligen FeLV/RCP is given to kittens as two injections under the skin.
Cepivo Leucofeligen FeLV/RCP se daje mačjim mladičem v obliki dveh injekcij pod kožo.
Leucofeligen FeLV/RCP is used to vaccinate cats from eight weeks of age against the following diseases:
Cepivo Leucofeligen FeLV/RCP se uporablja za cepljenje mačk, starejših od osem tednov, proti naslednjim boleznim:
Leucofeligen FeLV/RCP lyophilisate and solvent for suspension for injection
Leucofeligen FeLV/RCP liofilizat in vehikel za suspenzijo za injiciranje.
LEUCOFELIGEN FeLV/RCP lyophilisate and solvent for suspension for injection for cats
LEUCOFELIGEN FeLV/RCP liofilizat in vehikel za suspenzijo za injiciranje za mačke
Leucofeligen FeLV/RCP should not be used in pregnant cats.
Cepivo Leucofeligen FeLV/RCP se ne sme uporabljati pri brejih mačkah.
Leucofeligen FeLV/RCP, lyophylisate for cats
Leucofeligen FeLV/RCP liofilizat za mačke
Leucogen contains small amounts of a protein from the FeLV called ‘envelope p45 protein’.
Cepivo Leucogen vsebuje majhno količino beljakovine iz FeLV, imenovano beljakovina ovojnice p45.
Leucogen is a vaccine for cats that contains a protein of feline leukaemia virus (FeLV).
Leucogen je cepivo za mačke , ki vsebuje beljakovino virusa mačje levkemije (FeLV).
Leucogen is available as a suspension for injection.‌
Cepivo Leucogen je na voljo v obliki suspenzije za injiciranje.
Leucogen is given to kittens as two injections under the skin.
Cepivo Leucogen se daje mačjim mladičem v obliki dveh injekcij pod kožo.
Leucogen is used to vaccinate cats from eight weeks of age against feline leukaemia (an illness affecting the immune system caused by a retrovirus).
Leucogen se uporablja za cepljenje mačk od osmega tedna starosti proti mačji levkemiji (bolezni, ki prizadene imunski sistem in jo povzroča retrovirus).
Leucogen should not be used in pregnant cats.
Cepivo Leucogen se ne sme uporabljati pri brejih mačkah.
Leucogen suspension for injection
Leucogen suspenzija za injiciranje.
Leucogen suspension for injection for cats
Leucogen suspenzija za injiciranje za mačke.
leucopaenia
levkopenija
leucopaenia (including neutropaenia and
levkopenija (vključno z nevtropenijo in
Leucopenia
levkopenija
Leucopenia (2)
levkopenija (2)
Leucopenia and aggravated neutropenia
levkopenija in poslabšanje nevtropenije
leucopenia,
levkopenija,
leucopenia, neutropenia
levkopenija, nevtropenija
Leucopenia, thrombocytopenia
levkopenija, trombocitopenija
Leucopenia, thrombocytopenia, anaemia
levkopenija, trombocitopenija, anemija
Leucopenia: leucopenia associated with bexarotene therapy has been reported in clinical studies.
Levkopenija: V kliničnih študijah so poročali o povezanosti levkopenije z beksarotensko terapijo.
Leucopenia: The incidence of leucopenia reported as an adverse event was 4% in the group receiving Benlysta and 2% in the group receiving placebo.
Levkopenija: Incidenca levkopenije kot neželenega učinka je bila v skupini, ki je prejemala zdravilo Benlysta, 4 % in v skupini, ki je prejemala placebo, 2 %.
Leucovorin
levkovorin
Leucovorin (75 mg/m2 at hour 36, IV; 15 mg/m2 IV or PO q6h x 6 doses)iii: Days 2, 3, 16, and 17
levkovorin (75 mg/m2 36 ur po začetku, i.v.; 15 mg/m2 i.v. ali peroralno vsakih 6 ur x 6 odmerkov) iii: 2., 3., 16. in 17. dan
Leucovorin on day 1 and 2
levkovorin 1. in 2. dan
Leucovorin on Days 1 and 2, every 2 weeks
levkovorin 1. in 2. dan, vsake 2 tedna
Leukaemia
III.
Leukaemia
levkemija,
leukaemia (cancer affecting the blood and bone marrow)
levkemija (rak, ki prizadene kri in kostni mozeg)
leukaemia (cancer affecting the blood and bone marrow);
levkemija (rak, ki prizadene kri in kostni mozeg);
Leukaemia (cancer affecting the blood and bone marrow); Merkel cell carcinoma (a type of skin cancer); excessive activation of white blood cells associated with inflammation (macrophage activation syndrome); recurrence of hepatitis B (a liver infection); worsening of a condition called dermatomyositis (muscle inflammation and weakness with an accompanying skin rash).
Levkemija (rak, ki prizadene kri in kostni mozeg); karcinom Merklovih celic (vrsta kožnega raka); čezmerna aktivacija belih krvničk, povezanih z vnetjem (sindrom aktivacije makrofagov); ponovitev hepatitisa B (vnetje jeter); poslabšanje stanja, imenovanega dermatomiozitis (vnetje mišic in mišična oslabelost, ki ju spremlja kožni izpuščaj).
leukaemia (cancer of the blood cells).
levkemijo (rakavo obolenje krvnih celic).
Leukaemia (This has been reported in a small number of growth hormone deficiency patients, some of whom have been treated with somatropin.
odrevenelost/ščemenje levkemija (O njej so poročali pri majhnem številu bolnikov s pomanjkanjem rastnega hormona, pri čemer so bili nekateri zdravljeni s somatropinom.
Leukaemia and in elderly patients, skin cancers
kevkemija pri starejših bolnikih, kožni rak
Leukaemia has been reported in a small number of growth hormone deficiency patients, some of whom have been treated with somatropin.
Pri majhnem številu bolnikov s pomanjkanjem rastnega hormona, pri čemer so bili nekateri zdravljeni s somatropinom, so poročali o levkemiji.
leukaemia1)
levkemija1)
Leukaemia†
levkemija
Leukapheresis should be performed during the period when the ANC rises from < 0.5 x 109/l to > 5.0 x 109/l.
Levkaferezo je treba opravljati v času, ko se vrednost ANC poveča z < 0,5 x 109/l na > 5,0 x 109/l.
Leukapheresis should be started at day 5 and continued until day 6 if needed in order to collect 4 x 106 CD34+ cells/kg recipient bodyweight.
Levkaferezo je treba začeti 5. dan in z njo nadaljevati do 6. dne, če je potrebno, da bo zbranih 4 x 106 CD34+ celic/kg telesne mase prejemnika.
leukemia (cancer affecting the blood and bone marrow);
levkemija (rak, ki prizadene kri ali kostni mozeg);
leukemia (cancer affecting the blood and bone marrow);
levkemija (rak, ki prizadene kri in kostni mozeg);
Leuko- cytosis and lympho- cytosis
Levkocitoza in limfocitoza
Leukocyte Activation Syndrome (APL Differentiation Syndrome): 27% of patients with APL treated with TRISENOX have experienced symptoms similar to a syndrome called the retinoic-acid-acute promyelocytic leukaemia (RA-APL) or APL differentiation syndrome, characterised by fever, dyspnoea, weight gain, pulmonary infiltrates and pleural or pericardial effusions, with or without leukocytosis.
Sindrom aktivacije levkocitov (sindrom diferenciacije APL): Pri 27 % bolnikov z APL, ki so jih zdravili z zdravilom TRISENOX, so se pojavili simptomi, podobni sindromu, imenovanemu retinojska kislina – akutna promielocitna levkemija (RA-APL) ali sindrom diferenciacije APL, za katerega so značilni povišana telesna temperatura, dispneja, pridobivanje telesne mase, pljučni infiltrati in plevralni ali perikardialni izlivi, z levkocitozo ali brez nje.
leukocyte count < 3000/mm³
število levkocitov < 3.000/mm³
Leukocytes Decreased
Znižani levkociti
leukocytoclast
levkocitoklasti
Leukocytoclast ic vasculitis Purpura Angioedema*
levkocitoklastičn i vaskulitis purpura angioedem
leukocytoclastic vasculitis
levkocitokla stični vaskulitis
Leukocytoclastic vasculitis
Levkocitoklastični vaskulitis
Leukocytoclastic vasculitis
Levkocitoklastični vaskulitis.
leukocytoclastic vasculitis, skin fibrosis
levkocitoklastični vaskulitis, kožna fibroza
leukocytopenia, thrombocytopenia
levkocitopenija, trombocitopenija
Leukocytopenia, thrombocytopenia, allergic reactions, hyperglycaemia, hypertonia, peripheral neuropathy, myocardial infarction, arrhythmia (including bradycardia, ventricular tachycardia and atrial fibrillation), vasculitis, pancreatitis, gastritis, gingival hyperplasia, hepatitis, jaundice, hepatic enzymes increased*, angioedema, erythema multiforme, urticaria, exfoliative dermatitis, Stevens-Johnson syndrome, Quincke oedema, photosensitivity.
levkopenija, trombocitopenija, alergijske reakcije, hiperglikemija, hipertonija, periferna nevropatija, miokardni infarkt, aritmija (vključno z bradikardijo, ventrikularno tahikardijo in atrijsko fibrilacijo), vaskulitis, pankreatitis, gastritis, hiperplazija dlesni, hepatitis, zlatenica, zvišanje ravni jetrnih encimov*, angioedem, multiformni eritem, urtikarija, eksfoliativni dermatitis, Stevens-Johnsonov sindrom, Quinckejev edem, fotosenzitivnost
Leukocytosis (WBC > 50 x 109/L) was observed in 41 % of donors and transient thrombocytopenia (platelets < 100 x 109/L) following filgrastim and leukapheresis was observed in 35 % of donors.
Levkocitozo (število belih krvničk > 50 x 109/l) so opazili pri 41 % darovalcev, prehodno trombocitopenijo (število trombocitov < 100 x 109/l) pa pri 35 % darovalcev po odmerjanju filgrastima in po levkaferezi.
Leukocytosis (WBC > 50 x 109/l) was observed in 41% of donors and transient thrombocytopenia (platelets < 100 x 109/l) following filgrastim and leukapheresis was observed in 35% of donors (see section 4.4).
Levkocitozo (število levkocitov > 50 x 109/l) so opazili pri 41 % darovalcev, prehodno trombocitopenijo (število trombocitov < 100 x 109/l) pa so po dajanju filgrastima in levkaferezi ugotovili pri 35 % darovalcev (glejte poglavje 4.4).
Leukocytosis (white blood cell (WBC) > 50 x 109/l) was observed in 41% of donors and transient thrombocytopenia (platelets < 100 x 109/l) following filgrastim and leukapheresis was observed in 35% of donors (see section 4.4).
Levkocitozo (število belih krvničk > 50 x 109/l) so opazili pri 41 % darovalcev, prehodno trombocitopenijo (število trombocitov < 100 x 109/l) po prejemu filgrastima in levkaferezi pa pri 35% darovalcev (glejte poglavje 4.4).
Leukocytosis occurred in 50% of patients with APL, as determined by haematology assessments.
Levkocitoza se je pojavila pri 50 % bolnikov z APL.
Leukocytosis was observed in donors and thrombocytopenia following filgrastim and leukapheresis was also observed in donors.
Pri dajalcih so opazili levkocitozo, po dajanju filgrastima in po levkaferezi pa so pri dajalcih opazili tudi trombocitopenijo.
Leukocytosis was observed in donors and thrombocytopenia following filgrastim and leukapheresis was also observed in donors.
Pri darovalcih so opazili levkocitozo ter tudi trombocitopenijo po uporabi filgrastima in levkaferezo.
Leukocytosis was observed in donors and thrombocytopenia following filgrastim and leukapheresis was also observed in donors.
Pri darovalcih so opazili levkocitozo, po dajanju filgrastima in po levkaferezi pa so pri darovalcih opazili tudi trombocitopenijo.
Leukocytosis was observed in donors andthrombocytopenia following filgrastim and leukapheresis was also observed in donors.
Pri dajalcih so opažali levkocitozo in prav tako pri dajalcih so po filgrastimu in levkaferezi opažali trombocitopenijo.
Leukocytosis*, Splenomegaly*
levkocitoza*, splenomegalija
Leukocytosis, Lymphadenopathy
levkocitoza, limfadenopatija
Leukocytosis, thrombocytopenia
Levkocitoza, trombocitopenija
Leukocytosisa
levkocitozaa
Leukoenceph- alopathy, anosmia
levkoence- falopatija, anozmija
Leukoencephalopathy
Levkoencefalo- patija
Leukopaenia **
levkopenija
Leukopaenia, anaemia
levkopenija, anemija
Leukopaenia, anaemia, neutropaenia, thrombocytopaenia
levkopenija, anemija, nevtropenija, trombocitopenija
Leukopaenia, anaemia, thrombocytopaenia
levkopenija, anemija, trombocitopenija
Leukopenia
levkocitoza limfopenija
Leukopenia
levkopenija
Leukopenia (Leukopenia, White blood cell count decreased).
levkopenija (levkopenija, zmanjšano število belih krvničk)
Leukopenia Neutropenia Thrombocytopenia
levkopenija nevtropenija trombocitopenija
Leukopenia Neutropenia Thrombocytopenia
nevtropenija trombocitopenija
Leukopenia Thrombocytopaenia
levkopenija trombocitopenija
Leukopenia Thrombocytopenia
levkopenija trombocitopenija
Leukopenia Thrombocytopenia Febrile neutropenia Anaemia Pancytopenia Granulocytopenia
levkopenija trombocitopenija febrilna nevtropenija anemija pancitopenija granulocitopenija
Leukopenia*
levkopenija
Leukopenia**** Neutropenia**** Anemia****
levkopenija**** nevtropenija**** anemija
Leukopenia*, Lymphopenia*
levkopenija*, limfopenija